PubMed Health⌕ Search

Biomedical subjects

J Prignot

Publications and source records attributed to J Prignot.

At least 37 records · Page 2Linked to original sources
PubMed1988

Detection of small cell lung cancer bone marrow metastases by immunofluorescence.

It is well known that small cell lung cancer (SCLC) has a high propensity to metastasize to the bone marrow and that such involvement has a prognostic significance. A more accurate detection of these bone marrow metastases is thus mandatory. In this study, we analysed the results of the detection of these metastases using an indirect immunofluorescence test. For this purpose, 3 anti-SCLC rat monoclonal antibodies (MoAbs) specific for 3 different antigens (LCA1, LCA2, LCA3) have been utilized to examine 59 bone marrow samples from patients at time of diagnosis and 20 samples from chemotherapy treated patients. Eight patients had bone marrow clearly involved by morphological analysis. They all had fluorescent cells recognized at immunodetection with at least 2 MoAbs positive for 7 out of the 8 samples. Fifteen samples, negative by morphological analysis, were proven positive by immunofluorescence. In 12 cases, involvement was detected only by 1 MoAb (6 anti-LCA1, 2 anti-LCA2, 4 anti-LCA3). A correlation was found between the number of samples proven positive by morphological analysis and the number of positive MoAbs for these samples (p less than 0.005). Among the bone marrow samples provided by the 32 limited disease patients, LCA positive cells were detected in 9 (28%) compared to 14 out of the 27 (52%) samples from extensive disease patients (p less than 0.05). We concluded that the indirect immunofluorescence with a panel of MoAbs increases the rate of detection of bone marrow SCLC metastases.

Antibodies, Monoclonal↗
PubMed1987

Quantification and chemical markers of tobacco-exposure.

Quantitation of exposure to tobacco products is useful for any individual smoker, and necessary for epidemiological studies which relate smoking to pathology, or which are concerned with the efficacy of smoking cessation methods. The medical history, trying to quantitate the current mean daily cigarette consumption (consumption rate), the cumulative risk (pack years) and the various types of smoking, including inhalation habits, should also be attempted. However, due to the quasi-systematic underrating of tobacco consumption which smokers have revealed on many occasions, together with difficulty in correctly observing cigarette smoking, objective validation of recent historical data by quantitative measurement of tobacco products in tissue fluids is mandatory. Measurements of nicotine and cotinine levels in serum and urine require elaborate and expensive methods, and are not adequate for validation of smoking cessation in smokers who are using nicotine chewing gum. Carbon monoxide is a good marker of smoke inhalation. Normal carboxyhaemoglobin levels allow us to confirm that a subject has recently stopped smoking, as its half-life is only a few hours in blood. Salivary (or plasma) measurements of thiocyanate discriminate between smokers and ex-smokers, with a high probability, particularly in those who have stopped smoking for at least 14 days, separating these clearly from current smokers. However, several potential causes of error must be considered to allow correct interpretation of measurements of thiocyanate.

Carbon Monoxide↗
PubMed1986

Bronchodilating and density dependence effects of fenoterol, ipratropium bromide and Duovent in reversible chronic obstructive pulmonary disease.

The bronchodilating effect of Duovent (0.2 mg fenoterol +0.8 mg ipratropium bromide) was compared with that of each of its components at the same doses. Twenty patients were included in the trial. Maximum expiratory flow-volume curves with air and helium-oxygen, intrathoracic gas volume and airway conductance were used for assessing the bronchomotor tone before and 15, 30, 60, 240 and 360 min after drug administration. All the drugs showed a significant bronchodilating effect. No differences between Duovent and fenoterol or ipratropium bromide were observed except a slight but statistically significant greater decrease of ITGV with Duovent. When expressing the data as percentage variation of the initial values, Duovent induced a better effect than the other drugs. The evaluation of density dependence was highly disappointing, and no conclusion can be drawn.

Airway Resistance↗
PubMed1985

Influence of hyposensitization with Dermatophagoides pteronyssinus extract on clinical score, total and specific IgE levels, and skin test in asthmatic patients.

To evaluate the effects of immunotherapy on clinical response, on IgE serum level, on radioallergosorbent test (RAST), and on skin tests, a prospective study was performed by a follow-up of 73 asthmatic patients allergic for house dust during hyposensitization with Dermatophagoides pteronyssinus extract. No relationship could be found between the evolution of clinical score, skin tests and RAST, but 91% of the patients with a decreasing IgE serum level had satisfactory clinical results. Serial determinations of serum IgE levels during hyposensitization showed two patterns of evolution with a favourable prognostic value: a continuously decreasing serum IgE or a primary increase followed by a late decrease.

Allergens↗
PubMed1984

Comparison of the bronchodilating effect of two doses of a sustained release theophylline.

In order to assess the dose/response ratio of two different doses of theophylline, the effects of two periods of 4-day treatment with 300 and 450 mg sustained release anhydrous theophylline (Theodur, Astra, Sweden) b.i.d. in 16 in-patients with reversible chronic obstructive lung disease in a stable state were investigated in a double-blind randomized crossover study. On the 4th day in each treatment period, ventilatory function parameters (FEV1, FVC, PEFR, MEF25, MEF50), theophylline serum concentration and blood gases were measured. Asthma symptoms, beta 2-adrenergic aerosol use significantly different from its value before treatment: the mean FEV1 increase during the 300-mg period reached 12% and during the 450-mg period 15%. The mean difference in theophylline serum concentration between the periods of 300 and 450 mg reached approximately 2 micrograms/ml, but a significant difference could not be demonstrated between both treatment periods, neither in the mean ventilatory parameters, nor in the patients preference. In spite of the use of a sustained release preparation, variations of serum levels of theophylline were observed individually throughout a 12-hour observation period: the extent of those variations differs from one patient to another.

Adult↗
PubMed1983

Three-drug chemotherapy combined with radiation therapy in small cell carcinoma of the lung.

In 43 cases of small cell carcinoma of the lung, a combined treatment has been initiated with three drugs (cyclophosphamide 750 mg/m2, adriamycin 50 mg/m2 and vincristine sulphate 1 or 2 mg total dosage), split-course-radiation therapy on the primary tumour (3500 rads) and prophylactic irradiation of the brain (2000 rads). The median survival of the 34 cases evaluable at day 50 attains 253 days. A more favourable evolution is observed for patients with a good response after therapy (median survival: 315 days) and for cases with limited disease (321 days) than for non-responders (median survival: 157 days) and for cases with extensive disease (median survival: 214 days). In spite of tumour site irradiation, prophylactic irradiation of CNS and chemotherapy, there were six local relapses, two CNS extensions and six metastatic relapses and only two autopsied cases without macroscopic evidence of relapse.

Adult↗
PubMed1983

Influence of different extension-actuator tubes on the bronchodilation effect of a terbutaline sulfate aerosol.

The addition of a tube extension or of a pear-shaped spacer to a conventional metered-dose aerosol for delivering a bronchodilator drug, caused a slightly improved bronchodilation in 12 trained, adult patients with stable, reversible airways obstruction of moderate severity. Although statistically significant, the increase in bronchodilation effect does not appear to be clinically relevant in these patients. Continuous measurement of pulmonary resistance using the airflow interruption method did not reveal differences in the time of onset of the bronchodilation.

Administration, Oral↗
PubMed1981

Early bronchodilating effect of oxitropium bromide in comparison with ipratropium bromide.

The bronchodilating effects of a metered aerosol dose of 40 micrograms ipratropium bromide and of 200 micrograms oxitropium bromide are similar 15 min. after administration. The bronc hodilating activity of ipratropium bromide appears earlier (i.e., 75-90 s after administration) than that of oxitropium bromide but later than that of ibuterol, a beta2-agonist. Ipratropium bromide administered at the close of 80 micrograms provokes a bronchodilation about double of that obtained with 40 micrograms. An adaptation of the usual dosage should be considered.

Airway Resistance↗
PubMed1980

Controlled trial of the effect of repeated administration of ipratropium bromide on ventilatory function of patients with severe chronic airways obstruction.

A trial was designed to assess whether repeated administration of ipratropium bromide for two weeks produced greater improvement than was obtained after a single dose. The effect of ipratropium bromide was compared with that of a placebo during a double-blind cross-over randomized trial in patients with advanced chronic airways disease in a stable state. Ipratropium bromide and placebo were both administered by metered dose inhaler for 14 days. There was a slight statistically significant improvement of conductance, thoracic gas volume, FEV1 and VC after inhalation of ipratropium bromide, but repeated doses of the drug did not produce progressive improvement.

Airway Obstruction↗
PubMed1980

Evaluation of onset of bronchodilating effect by interruption of the air flow method.

The speed of onset of the bronchodilating effect of ibuterol, a derivative of terbutaline, was measured by the method of air flow interruptions, which enables an almost continuous study of lung resistance before and after the administration of a bronchodilator. In the double-blind comparison between ibuterol and placebo, the onset of action of the new beta 2-agonist has been shown to take place within 30-45 sec. This indicates that ibuterol is a bronchodilator with rapid onset of action.

Adult↗